読み込み中
NASDAQHealthcareBiotechnology
最新データ
$3.31
−$0.11 · -3.22%
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
前日終値
$3.31
−$0.11 · -3.22%
日中の時刻はETです。市場データは遅延する場合があります。
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
日中レンジ
現在 $3.31
52週レンジ
現在 $3.31
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
51
適正価値
センチメント
63
強気
リスク
60
やや高いリスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
日中レンジ
現在 $3.31
52週レンジ
現在 $3.31
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1.21億 USD | 7310.7万 USD | 5628.6万 USD | — | — |
| 販売・一般管理 | 2462万 USD | 775.6万 USD | 848.5万 USD | 3520 USD | 4.34万 USD |
| 営業費用 | 1.46億 USD | 8086.3万 USD | 6477.1万 USD | 3520 USD | 4.34万 USD |
| 受取利息 | 1134.3万 USD | 637.7万 USD | 7.2万 USD | — | — |
| 減価償却費と償却費 | 61万 USD | 20.8万 USD | 9.2万 USD | 3520 USD | — |
| 営業利益 | −1.46億 USD | −8086.3万 USD | −6477.1万 USD | −3520 USD | −4.34万 USD |
| 純利益 | −1.34億 USD | −7427.5万 USD | −6469.9万 USD | −3520 USD | −4.34万 USD |
会社概要が更新されました 2026年10月10日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1252.15万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF491.01万0.01%954億 USD0.05%$235+0.80%
State Street SPDR S&P Biotech ETFXBI228.24万0.02%98.74億 USD0.35%$153.77+3.00%
iShares Biotechnology ETFIBB126.83万0.01%102.79億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA77.75万0.00%218.24億 USD0.03%$32.79+0.40%
Virtus Biotech Clinical Trials ETFBBC14万0.34%4099.65万 USD0.65%$44.1456+2.08%
Direxion Daily S&P Biotech Bull 3X SharesLABU10.79万0.02%5.97億 USD0.96%$243.09+9.01%
Schwab U.S. Broad Market ETFSCHB9.48万0.00%453.77億 USD0.03%$29.91+0.61%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVirtus Biotech Clinical Trials ETFBBCDirexion Daily S&P Biotech Bull 3X SharesLABUSchwab U.S. Broad Market ETFSCHBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
